Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FAVON
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RC88-Mc-Val-Cit-PAB-MMAE
|
|||||
| Synonyms |
WO2019223579A1
Click to Show/Hide
|
|||||
| Organization |
RemeGen Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-MSLN mAb
|
Antibody Info | ||||
| Antigen Name |
Mesothelin (MSLN)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 99
|
%
|
Oval-CitAR-3 cells
|
Ovarian cancer
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
0.1
|
nM
|
Oval-CitAR-3 cells
|
Ovarian cancer
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.00% (Day 21) | High MSLN expression (MSLN+++/++) | ||
| Method Description |
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (2 mg/kg, qwx3) via the tail vein on Day 0.
|
||||
| In Vivo Model | Oval-CitAR-3 CDX model | ||||
| In Vitro Model | Ovarian cancer | Oval-CitAR-3 cells | Homo sapiens | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10 nM | High MSLN expression (MSLN+++/++) | ||
| Method Description |
Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
|
||||
| In Vitro Model | Ovarian cancer | Oval-CitAR-3 cells | Homo sapiens | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.